SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a sharp sell-off as investors react to the company's WWDC announcements, which many community members view as an underwhelming 'sell the news' event. While Apple unveiled a significant AI overhaul for Siri and new cloud-based computing strategies, the community is actively debating the company's innovation timeline, its reliance on partnerships like Google's Gemini, and whether the current valuation can be sustained.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is experiencing significant volatility and downward pressure as shareholders express growing frustration over executive turnover and the lack of a major partnership catalyst. Despite the company's strong cash position and the recent appointment of a new CFO, the community remains deeply divided, with many debating whether the stock is an oversold long-term value play or a broken asset struggling with structural instability.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is trending as investors scrutinize a fresh 80 million dollar common stock and warrant offering, which has sparked intense debate over the company's capital management, leadership efficacy, and fears of further dilution. Community sentiment remains deeply divided between long-term supporters clinging to the potential of the Eversense 365 implantable technology and disillusioned shareholders demanding accountability for recurring capital raises and persistent stock price stagnation.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as investors react to the company's strong earnings report and the broader sector's anticipation of federal rescheduling. Community sentiment remains focused on the company's profitability and stock buyback program, with many discussing its potential to be a long-term leader as institutional interest in the cannabis sector grows.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is experiencing strong momentum and is trending due to institutional accumulation and heavy insider buying, with community members actively discussing a technical breakout from long-term consolidation. Investors are focused on the company's path to profitability and recent revenue growth as market sentiment shifts toward healthcare disruptors.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF is seeing heightened engagement driven by Trulieves historic NYSE uplisting and broader anticipation for the DEAs upcoming rescheduling hearings. Investors are actively debating the impact of these milestones on sector-wide institutional capital access and the structural advantages of holding underlying MSO stocks versus the ETF.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is attracting significant community attention following its collaborative deal with Amazon Web Services, which positions the company as a key infrastructure provider for private cloud connectivity. Investors are actively debating the stock's long-term potential as a foundational AI play while closely watching upcoming earnings and management's progress on reducing debt and scaling fiber demand.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors as the community analyzes upcoming earnings and anticipation builds for potential clinical data readouts regarding their lead asset, soquelitinib. While some participants are wary of volatility and the biotech sector's broader trends, others are actively discussing the stock's potential for institutional interest and long-term pipeline development.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as positive reports suggest U.S. antitrust regulators are moving toward approving the Warner Bros. Discovery acquisition, with management actively addressing concerns over theatrical distribution. The community remains deeply divided, with many retail investors expressing frustration over prolonged share price stagnation while others hold out hope for a significant recovery driven by deal-related synergies.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending as investors focus on the company's strategic pivot toward AI infrastructure and its massive Helios data center project, which remains a key point of community discussion and anticipation. Market participants are actively tracking the potential for imminent tenant announcements and the stock's decoupled behavior from broader crypto volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets.read...

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech Q1 Earnings Call Highlights...

Legend Biotech (LEGN) Projected to Post Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Zurcher Kantonalbank Zurich Cantonalbank Decreases Stake in Legend Biotech Corporation Sponsored ADR $LEGN

Zurcher Kantonalbank Zurich Cantonalbank lowered its stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 89.4% in the fourth quarter, according to the company in its most...

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen research firms that are currently covering the...

Legend Biotech Corporation Sponsored ADR $LEGN Stock Holdings Lowered by Matthews International Capital Management LLC

Matthews International Capital Management LLC reduced its holdings in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 7.0% during the 4th quarter, according to its most recent...

Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?

Legend Biotech (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

HC Wainwright Reaffirms "Buy" Rating for Legend Biotech (NASDAQ:LEGN)

HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Legend Biotech in a report on Tuesday...

Why Legend Biotech Stock Crushed the Market on Monday

Key PointsThis followed a sizable acquisition of a peer biotech by a pharmaceutical sector giant...

LEGN Stock Clocks Best Day In Three Years — What’s Driving The Rally?

Equity

After Eli Lilly and Company bought Kelonia to advance CAR-T cell therapies, retail traders are now speculating a buyout for Legend. 


Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Current Price	$31.52
Prev Close	$32.62
Open	$32.50
Dividend Yield	0.00%
50-Day Moving Average	$25.01
Beta	0.57
Avg. Volume	2.44M
PE Ratio	-23.17

52-Week High	$45.30
52-Week Low	$16.24
Market Capitalization	$5.85B
EPS (Annual)	-$1.61
Price to Book	6.05
Revenue Per Employee	$355,731.44

LEGNLegend Biotech

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LEGN News